First-trimester screening biochemical markers (free beta-subunit human chorionic gonadotropin, pregnancy-associated plasma protein-A) and risk of early fetal loss

2014 ◽  
Vol 41 (1) ◽  
pp. 69-76 ◽  
Author(s):  
Henar Valbuena ◽  
Jordi Ramis ◽  
Juan Sagalá ◽  
Mª Ángeles Sánchez ◽  
Carlos Aulesa
Keyword(s):  
Chorionic Gonadotropin ◽  
Plasma Protein ◽  
Human Chorionic Gonadotropin ◽  
Biochemical Markers ◽  
Protein A ◽  
Fetal Loss ◽  
First Trimester ◽  
Beta Subunit ◽  
First Trimester Screening ◽  
Trimester Screening

The Effect of Chemical Compounds from Cigarettes Smoke on First Trimester Biochemical Markers

2017 ◽  
Vol 68 (9) ◽  
pp. 2122-2124
Author(s):  
Adrian Carabineanu ◽  
Dan Navolan ◽  
Florin Birsasteanu ◽  
Octavian Cretu ◽  
Marioara Boia ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Chorionic Gonadotropin ◽  
Biochemical Markers ◽  
Protein A ◽  
Chemical Compounds ◽  
First Trimester ◽  
Physical Parameters ◽  
First Trimester Screening ◽  
Trimester Screening ◽  
The Relationship

Previous studies showed that certain behavioral and physical parameters influence the concentration of first trimester biochemical markers. The scope of the present article was to study the relationship between smoking and first trimester screening biochemical markers and the capability of the software to counterbalance this influence. Concentrations of pregnancy-associated protein A (PAPP-A) and free b chorionic gonadotropin hormone (free b hCG) were measured in sera of 1554 first trimester pregnant women, 1349 of which were non-smokers and 205 were smokers. First trimester PAPP-A values are lower in smoking compared to non-smoking pregnant women (0.94�0.04 vs. 1.09�0.02, p=0.0004), since smoking seems not to influence free b hCG concentration (1.11�0.07 vs. 1.03�0.02, ns). The software used by us corrected successfully the effect of chemical compounds from cigarette smoke on PAPP-A values.

Four Years' Experience With an Interlaboratory Comparison Program Involving First-Trimester Markers of Down Syndrome

2010 ◽  
Vol 134 (11) ◽  
pp. 1685-1691
Author(s):  
Glenn E. Palomaki ◽  
George J. Knight ◽  
Geralyn Lambert-Messerlian ◽  
Jacob A. Canick ◽  
James E. Haddow
Keyword(s):  
Down Syndrome ◽  
Chorionic Gonadotropin ◽  
Plasma Protein ◽  
Human Chorionic Gonadotropin ◽  
Interlaboratory Comparison ◽  
Protein A ◽  
First Trimester ◽  
Nuchal Translucency ◽  
Second Trimester ◽  
Coefficients Of Variation

Abstract Context.—We initiated a voluntary, self-funded interlaboratory comparison program in the fall of 2005 because no proficiency testing program was available to laboratories in North America offering first-trimester, combined serum and ultrasound, Down syndrome screening. Objectives.—To evaluate the first 4 years of the interlaboratory comparison program against stated goals, to identify areas of concern, and to create new initiatives as indicated. Design.—Five serum samples are distributed 3 times a year to be tested for pregnancy-associated plasma protein A, human chorionic gonadotropin or its β subunit, and dimeric inhibin-A; participants convert these results into multiples of the median. Patient histories include nuchal translucency information that enables the calculation of the risk of Down syndrome. Also included are educational components linked to interlaboratory comparison program results. Assessment of integrated (first- and second-trimester markers) risks is accomplished by having participants combine interlaboratory comparison program results with their results from a second-trimester proficiency testing program administered by the College of American Pathologists. Results.—The precision profile for pregnancy-associated plasma protein A shows decreasing coefficients of variation with increasing pregnancy-associated plasma protein A concentrations and multiples of the median (25% to 11% and 30% to 15%, respectively). In contrast, coefficients of variation are a relatively constant 12% throughout the entire range of human chorionic gonadotropin results. On a logarithmic scale, the median coefficient of variation of the risk of Down syndrome is 9%. Conclusions.—Participants in the interlaboratory comparison program reliably measure analytes, compute multiples of the median, and calculate consistent Down syndrome risks. Assays for the measurement of pregnancy-associated plasma protein A are not standardized and are less precise than those for human chorionic gonadotropin. Participants calculate reliable median equations given sonographer-specific sets of paired crown-rump length and nuchal translucency measurements.

Sign in / Sign up

Export Citation Format

Share Document